Vijay Elakkya¹ ,Dr.NS.Raja.²¹Student,Department of Genetic Engineering,School of Bioengineering, Kattankulathur,603-203 Tamil Nadu,India.
²Assistant Professor,Department of Genetic Engineering,School of Bioengineering, Kattankulathur,603-203 Tamil Nadu,India.
Abstract
Renal cell carcinoma (RCC) is a devastating disease often refractory to radiation, chemo and cytokine therapy. Agents targeting the vascular endothelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathways remain the mainstay for the management of RCC. However, the benefits of these agents have been tempered by the fact that not all patients respond to these treatments, and amongst those that do, the responses are not durable and associated with toxicities. Efforts to extend the clinical benefits of these agents with combination therapy have resulted in clinically prohibitive high-grade dose-limiting toxicities; often with no overall benefit. Two different approaches which are expected to show better results have been experimented. Clinical observation has proved the synergistic efficacy of ACEi (Angiotensin converting enzyme inhibitors) and Anti-VEGF therapy to be greater when compared to the use of agents that target only VEGF. It is extensively known that KIM 1 is a biomarker for Renal Cell Carcinoma at an early stage. C.onstructing a nano carrier with the drug dressed with KIM 1 antibody helps in delivering the drug to the tissue directly. This type of carrier systems helps to overcome problems such as drug degradation and leakage.
Date: 13.08.14
Time : 10.00am
Department of Genetic Engineering
SRM University